Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma
- PMID: 1457613
- DOI: 10.1515/cclm.1992.30.9.521
Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma
Abstract
The interferon-inducible enzyme, 2'-5'-oligoadenylate synthetase, was estimated in healthy donors and in patients before and after subcutaneous application of recombinant interferon beta and gamma. Tests were carried out with lysates of peripheral blood mononuclear cells, using an established radioenzymatic assay, and in serum samples, using a new radioimmunoassay. Both test systems substantially yielded the same results: after a single injection of interferon beta (1-5 x 10(6) IU), 2'-5'-oligoadenylate synthetase increased in a dose-dependent manner reaching maximal catalytic concentrations in most patients after 24-48 hours (leukocytes) and 48-72 hours (serum). In contrast, interferon gamma (2-4 x 10(6) IU) caused only a small induction of 2'-5'-oligoadenylate synthetase. However, daily application of interferon gamma for 7 days led to a distinct time-dependent increase of 2'-5'-oligoadenylate synthetase activity concentration during this observation period. Characteristically, even during daily application, the 2'-5'-oligoadenylate synthetase activity concentration dropped just 48-72 hours after the first injection of interferon beta. The determination of 2'-5'-oligoadenylate synthetase proved to be useful for optimizing and monitoring subcutaneous therapy with interferon. The new radioimmunoassay which allows the determination of this enzyme in serum is superior to other methods used in the past.
Similar articles
-
Methods for the determination of the interferon-induced enzyme 2'-5' oligoadenylate synthetase in mononuclear blood cells.J Clin Chem Clin Biochem. 1987 Dec;25(12):879-88. doi: 10.1515/cclm.1987.25.12.879. J Clin Chem Clin Biochem. 1987. PMID: 2450958
-
Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.Hepatology. 1988 Mar-Apr;8(2):366-70. doi: 10.1002/hep.1840080229. Hepatology. 1988. PMID: 2451634
-
Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.J Interferon Cytokine Res. 1996 Oct;16(10):759-64. doi: 10.1089/jir.1996.16.759. J Interferon Cytokine Res. 1996. PMID: 8910759 Clinical Trial.
-
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8. doi: 10.1093/jnci/81.14.1061. J Natl Cancer Inst. 1989. PMID: 2472488 Clinical Trial.
-
[Interferon (IFN)-alpha, beta, gamma].Nihon Rinsho. 2005 Aug;63 Suppl 8:89-92. Nihon Rinsho. 2005. PMID: 16149460 Review. Japanese. No abstract available.
Cited by
-
Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.Cancer Immunol Immunother. 1995 Mar;40(3):157-64. doi: 10.1007/BF01517347. Cancer Immunol Immunother. 1995. PMID: 7728774 Free PMC article. Clinical Trial.
-
The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.Pharmacol Ther. 1998 May;78(2):55-113. doi: 10.1016/s0163-7258(97)00167-8. Pharmacol Ther. 1998. PMID: 9623881 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous